Lithium for Parkinson's: an Extension Trial
Enrolling by invitation · Phase 1/Phase 2
Conditions studied: Parkinson Disease
In brief
This study will examine the effects of 24 weeks of lithium therapy achieving serum lithium levels of 0.25-0.50mmol/L on MRI and blood-based biomarkers in Parkinson's disease patients who have completed one of our current 24-week lithium clinical trials.
Key facts
- Study ID
- NCT06592014
- Run by
- State University of New York at Buffalo
- People needed
- 35
- Starts
- 2024-08-09
- Expected to finish
- 2026-11-01
- Last updated by the study team
- 2025-11-19
Who can join
Age: 45 and older, up to 80. Sex: any. Healthy volunteers: not accepted.
Where it is running
- UBMD Neurology — Williamsville, New York, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.